Nasdaq

Clearside Biomedical Details Phase 3 Program for CLS-AX in Wet AMD Following Positive FDA Meeting

Receipt of formal meeting minutes from the FDA confirming key elements for two proposed Phase 3 pivotal trials indicates regulatory progress and alignment with the FDA. Positive outcome of the ...
Nasdaq

Clearside Biomedical Highlights CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial at Upcoming Conferences

Clearside Biomedical announces upcoming presentations on CLS-AX sub-group analyses from the ODYSSEY Wet AMD trial at various conferences. Clearside Biomedical, Inc. announced upcoming presentations ...
Seeking Alpha

Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Summary: This presentation compared the benefits of TKIs in wet AMD management, focusing on pan-VEGF receptors blockage and extended drug delivery while acknowledging the limitations of current ...
WRIC

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

ALPHARETTA, Ga., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
Seeking Alpha

ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing ...
Business Insider

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial - - CLS-AX Targets Flexible Dosing of Biologics with Duration of ...